Common Contracts
6 similar Exclusive Agency Agreement contracts by Apricus Biosciences, Inc., Capstone Therapeutics Corp., Cytrx Corp, others
STRICTLY CONFIDENTIAL Gevo, Inc.Exclusive Agency Agreement • June 1st, 2018 • Gevo, Inc. • Industrial organic chemicals • New York
March 27, 2018Exclusive Agency Agreement • March 29th, 2018 • Apricus Biosciences, Inc. • Pharmaceutical preparations • New York
This letter agreement (this “Agreement”) constitutes the agreement between Apricus Biosciences, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (the “Securities”) during the Term (as defined below) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in c
STRICTLY CONFIDENTIAL Attn: Richard W. PascoeExclusive Agency Agreement • September 11th, 2017 • Apricus Biosciences, Inc. • Pharmaceutical preparations • New York
This letter agreement (this “Agreement”) constitutes the agreement between Apricus Biosciences, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (the “Securities”) during the Term (as defined below) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in c
STRICTLY CONFIDENTIAL CytRx Corporation 11726 San Vicente Blvd., Suite 650 Los Angeles, CA 90049 Attn: John Y. Caloz, Chief Financial Officer Dear Mr. Caloz:Exclusive Agency Agreement • April 28th, 2017 • Cytrx Corp • Biological products, (no disgnostic substances) • New York
This letter agreement (this “Agreement") constitutes the agreement between CytRx Corporation (the “Company") and H.C. Wainwright & Co., LLC (“Wainwright”). that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (“Securities”) during the Term (as defined below) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in connection wi
Ohr Pharmaceutical, Inc. - 8-KExclusive Agency Agreement • December 8th, 2016 • Ohr Pharmaceutical Inc • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIALExclusive Agency Agreement • September 16th, 2015 • Capstone Therapeutics Corp. • Pharmaceutical preparations • New York
This letter agreement (this “Agreement”) constitutes the agreement between Capstone Therapeutics Corp. (excluding the Company’s subsidiary, Lipimetix Development, Inc., the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”) that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (“Securities”) during the Term (as defined below) of this Agreement The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances an
